Pratteln, Switzerland, March 1, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces positive results from its multiple ascending dose Phase 1b study with lonodelestat, a potent inhibitor of human neutrophil elastase (hNE), in patients with cystic fibrosis (CF).

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *